Destiny
Pharma plc
("Destiny
Pharma" or "the Company")
Director/PDMR Shareholding
Brighton, United Kingdom - 5
August 2024 - Destiny Pharma plc (AIM:
DEST), a clinical stage biotechnology company focused on the
development and commercialisation of novel medicines to prevent and
cure life-threatening infections, announces that it was notified on
2 August 2024 that on that same day, Sir Nigel Rudd, Chairman of
the Company, purchased 1,240,000 ordinary shares
of 1
pence each in
the Company ("Ordinary Shares") at a price of 2.5 pence.
Following this purchase, Sir Nigel
Rudd's beneficial interest in the Company (together with his
spouse) is 3,761,716 Ordinary Shares, representing 3.93 per cent of
the total issued share capital.
For
further information, please contact:
Destiny Pharma plc
Chris Tovey, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
pressoffice@destinypharma.com
FTI
Consulting
Ben Atwell / Simon Conway
+44 (0) 203 727 1000
destinypharma@fticonsulting.com
Shore Capital (Nominated Adviser and Broker)
Daniel Bush / James Thomas / Lucy
Bowden
+44 (0) 207 408 4090
About Destiny Pharma
Destiny Pharma is an innovative,
clinical-stage biotechnology company focused on the development and
commercialisation of novel medicines that can prevent
life-threatening infections. The Company's drug development
pipeline includes two late-stage assets XF-73 Nasal gel, a
proprietary drug targeting the prevention of post-surgical
staphylococcal hospital infections including MRSA and NTCD-M3, a
microbiome-based biotherapeutic for the prevention of C. difficile
infection (CDI) recurrence which is the leading cause of hospital
acquired infection in the US.
For further information on the
company, please visit
www.destinypharma.com
This announcement contains inside
information for the purposes of Article 7 of the Market Abuse
Regulation (EU) 596/2014 as it forms part of UK domestic
law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"),
and is disclosed in accordance with the company's obligations under
Article 17 of MAR.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
|
1.
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Sir Nigel Rudd
|
|
2.
|
Reason for the Notification
|
|
a)
|
Position/status
|
Chairman
|
|
b)
|
Initial
notification/Amendment
|
Initial notification
|
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Destiny Pharma plc
|
|
b)
|
LEI
|
213800O9WH9Z38EHAC95
|
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the Financial
instrument, type of instrument
|
Ordinary shares of 1
pence each
|
|
Identification code
|
DEST
GB00BDHSP575
|
|
b)
|
Nature of the transaction
|
Purchase of Ordinary
Shares
|
|
c)
|
Price(s) and volume(s)
|
2.5 pence
1,240,000 Ordinary
Shares
|
|
d)
|
Aggregated information:
Aggregated volume
Price
|
See 4c) above
|
|
e)
|
Date of the transaction
|
2 August 2024
|
|
f)
|
Place of the transaction
|
London Stock Exchange, AIM market
(XLON)
|